Hormone receptor positive HER2 negative breast cancer
Not yet recruitingStudy on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer
Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibGiredestrant+1
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Medica Scientia Innovation Research S.L.










